A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors

Summary

Phase I single-institution, open-label, dose-escalating, clinical and pharmacokinetic study. The purpose is to determine the safety, tolerability and to identify the dose limiting toxicities(DLT) and recommended dose (RD) of PM02734 administered every 3 weeks, intravenously, over 30 minutes to subjects with advanced malignant solid tumors.

Timeline

Start

2005-08

Primary completion

2011-05

Completion

2011-05

Outcome

Outcome not reported

Stopped (Enrollment): “Low rate recruitment”

Drugs

Indications